AU2005327929A1 - Identification of molecular diagnostic markers for endometriosis in blood lymphocytes - Google Patents
Identification of molecular diagnostic markers for endometriosis in blood lymphocytes Download PDFInfo
- Publication number
- AU2005327929A1 AU2005327929A1 AU2005327929A AU2005327929A AU2005327929A1 AU 2005327929 A1 AU2005327929 A1 AU 2005327929A1 AU 2005327929 A AU2005327929 A AU 2005327929A AU 2005327929 A AU2005327929 A AU 2005327929A AU 2005327929 A1 AU2005327929 A1 AU 2005327929A1
- Authority
- AU
- Australia
- Prior art keywords
- endometriosis
- value
- gene expression
- level
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000009273 Endometriosis Diseases 0.000 title claims description 122
- 210000004698 lymphocyte Anatomy 0.000 title description 16
- 230000014509 gene expression Effects 0.000 claims description 162
- 108090000623 proteins and genes Proteins 0.000 claims description 145
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 101001043321 Homo sapiens Lysyl oxidase homolog 1 Proteins 0.000 claims description 28
- 102100021958 Lysyl oxidase homolog 1 Human genes 0.000 claims description 28
- 210000005259 peripheral blood Anatomy 0.000 claims description 26
- 239000011886 peripheral blood Substances 0.000 claims description 26
- 210000000265 leukocyte Anatomy 0.000 claims description 24
- 102100021763 Alpha-mannosidase 2x Human genes 0.000 claims description 21
- 101000615966 Homo sapiens Alpha-mannosidase 2x Proteins 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 20
- 238000004458 analytical method Methods 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 16
- 239000002299 complementary DNA Substances 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 101100189590 Mus musculus Pde6b gene Proteins 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 238000010208 microarray analysis Methods 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 claims description 5
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 44
- 239000000523 sample Substances 0.000 description 37
- 229920001184 polypeptide Polymers 0.000 description 36
- 201000010099 disease Diseases 0.000 description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- 102100040247 Tumor necrosis factor Human genes 0.000 description 26
- 238000003752 polymerase chain reaction Methods 0.000 description 26
- 238000003556 assay Methods 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 102000001770 Low Density Lipoprotein Receptor-Related Protein-5 Human genes 0.000 description 19
- 108010015167 Low Density Lipoprotein Receptor-Related Protein-5 Proteins 0.000 description 19
- 238000002493 microarray Methods 0.000 description 19
- 150000007523 nucleic acids Chemical class 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 17
- -1 complement factors Proteins 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 238000012340 reverse transcriptase PCR Methods 0.000 description 13
- 238000000018 DNA microarray Methods 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 238000003753 real-time PCR Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 102100040682 Platelet-derived growth factor D Human genes 0.000 description 10
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000013615 primer Substances 0.000 description 9
- 238000010839 reverse transcription Methods 0.000 description 9
- 101000611892 Homo sapiens Platelet-derived growth factor D Proteins 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 7
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 208000000509 infertility Diseases 0.000 description 6
- 230000036512 infertility Effects 0.000 description 6
- 231100000535 infertility Toxicity 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 101000629643 Homo sapiens Signal recognition particle receptor subunit beta Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102100026904 Signal recognition particle receptor subunit beta Human genes 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 210000003567 ascitic fluid Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000006894 menstrual cycle phase Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101710147523 DNA damage-inducible protein 1 Proteins 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 102000047918 Myelin Basic Human genes 0.000 description 3
- 101710107068 Myelin basic protein Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 239000000104 diagnostic biomarker Substances 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000002357 laparoscopic surgery Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 101000983256 Acanthamoeba polyphaga mimivirus Putative prolyl 4-hydroxylase Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 101710189311 Cytokine receptor common subunit gamma Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 2
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102100026327 Oviduct-specific glycoprotein Human genes 0.000 description 2
- 101710113449 Oviduct-specific glycoprotein Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101710170209 Platelet-derived growth factor D Proteins 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000003499 nucleic acid array Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000092 prognostic biomarker Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- 102100037513 40S ribosomal protein S23 Human genes 0.000 description 1
- 101710131793 40S ribosomal protein S23 Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 1
- 101100367084 Caenorhabditis elegans such-1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 108010028778 Complement C4 Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000004240 Glycodelin Human genes 0.000 description 1
- 108010081520 Glycodelin Proteins 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 description 1
- 102100031153 Growth arrest and DNA damage-inducible protein GADD45 beta Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000740689 Homo sapiens C4b-binding protein beta chain Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 101001066164 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 beta Proteins 0.000 description 1
- 101000611643 Homo sapiens Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 description 1
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108010000837 Janus Kinase 1 Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 108010054377 Mannosidases Proteins 0.000 description 1
- 102000001696 Mannosidases Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000015766 Protein Kinase C beta Human genes 0.000 description 1
- 108010024526 Protein Kinase C beta Proteins 0.000 description 1
- 102100040714 Protein phosphatase 1 regulatory subunit 15A Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010051611 Signal Recognition Particle Proteins 0.000 description 1
- 102000013598 Signal recognition particle Human genes 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 201000002595 endometriosis of ovary Diseases 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 208000030747 ovarian endometriosis Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65433105P | 2005-02-18 | 2005-02-18 | |
| US60/654,331 | 2005-02-18 | ||
| PCT/US2005/044723 WO2006091254A1 (en) | 2005-02-18 | 2005-12-09 | Identification of molecular diagnostic markers for endometriosis in blood lymphocytes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2005327929A1 true AU2005327929A1 (en) | 2006-08-31 |
Family
ID=36182367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005327929A Abandoned AU2005327929A1 (en) | 2005-02-18 | 2005-12-09 | Identification of molecular diagnostic markers for endometriosis in blood lymphocytes |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090208939A1 (enExample) |
| EP (1) | EP1848818A1 (enExample) |
| JP (1) | JP2008537474A (enExample) |
| KR (1) | KR20080016789A (enExample) |
| CN (1) | CN101124340A (enExample) |
| AU (1) | AU2005327929A1 (enExample) |
| BR (1) | BRPI0520012A2 (enExample) |
| CA (1) | CA2596932A1 (enExample) |
| IL (1) | IL184920A0 (enExample) |
| MX (1) | MX2007009562A (enExample) |
| NO (1) | NO20074762L (enExample) |
| WO (1) | WO2006091254A1 (enExample) |
| ZA (1) | ZA200707752B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9222938B2 (en) * | 2001-12-04 | 2015-12-29 | Michael Tainsky | Neoepitope detection of disease using protein arrays |
| WO2008123901A2 (en) * | 2007-02-06 | 2008-10-16 | Genizon Biosciences | Genemap of the human genes associated with endometriosis |
| US8932993B1 (en) | 2007-06-11 | 2015-01-13 | Juneau Biosciences, LLC. | Method of testing for endometriosis and treatment therefor |
| WO2009140126A1 (en) * | 2008-05-14 | 2009-11-19 | Juneau Biosciences, Llc | Method of administering a therapeutic |
| WO2010124101A2 (en) | 2009-04-22 | 2010-10-28 | Juneau Biosciences, Llc | Genetic markers associated with endometriosis and use thereof |
| JP5503942B2 (ja) * | 2009-10-30 | 2014-05-28 | シスメックス株式会社 | 疾患の罹患の判定方法 |
| EP2348129A1 (en) * | 2010-01-21 | 2011-07-27 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
| KR101333207B1 (ko) * | 2011-07-13 | 2013-11-26 | 부산대학교 산학협력단 | 자궁내막증과 연관된 유전자 마커 및 이의 용도 |
| EP2773779B1 (en) | 2011-11-04 | 2020-10-14 | Population Bio, Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
| WO2013120018A1 (en) | 2012-02-09 | 2013-08-15 | Population Diagnostics, Inc. | Methods and compositions for screening and treating developmental disorders |
| KR101445560B1 (ko) | 2012-05-10 | 2014-09-29 | 한국수력원자력 주식회사 | 저준위 전리방사선에 민감한 유전자 검출 방법 및 상기 방법으로 검출된 유전자 |
| DK2895621T3 (da) | 2012-09-14 | 2020-11-30 | Population Bio Inc | Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande |
| US9434991B2 (en) | 2013-03-07 | 2016-09-06 | Juneau Biosciences, LLC. | Method of testing for endometriosis and treatment therefor |
| JP2016526888A (ja) * | 2013-06-28 | 2016-09-08 | アキュメン リサーチ ラボラトリーズ プライヴェット リミテッドＡｃｕｍｅｎ Ｒｅｓｅａｒｃｈ Ｌａｂｏｒａｔｏｒｉｅｓ Ｐｔｅ． Ｌｔｄ． | 敗血症バイオマーカー及びそれらの使用 |
| EP3511422B1 (en) | 2013-11-12 | 2022-12-28 | Population Bio, Inc. | Methods and compositions for diagnosing, prognosing, and treating endometriosis |
| DE102014203235A1 (de) * | 2014-02-24 | 2015-08-27 | Mahle International Gmbh | Klimagerät, insbesondere für ein Kraftfahrzeug und Verfahren zur Herstellung einer Komponente eines Klimagerätes |
| RU2558854C1 (ru) * | 2014-06-23 | 2015-08-10 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Способ прогнозирования риска развития эндометриоза |
| JP2016077234A (ja) * | 2014-10-17 | 2016-05-16 | 国立大学法人鳥取大学 | 子宮内膜症の早期診断のための診断キット、診断マーカー及び検出方法 |
| CN107326065B (zh) * | 2016-04-29 | 2022-07-29 | 博尔诚（北京）科技有限公司 | 一种基因标识物的筛选方法及其应用 |
| CN107858415B (zh) * | 2016-09-19 | 2021-05-28 | 深圳华大生命科学研究院 | 用于子宫腺肌症检测的生物标志物组合及其应用 |
| US10240205B2 (en) | 2017-02-03 | 2019-03-26 | Population Bio, Inc. | Methods for assessing risk of developing a viral disease using a genetic test |
| US10729693B2 (en) * | 2018-03-02 | 2020-08-04 | Ponce Medical School Foundation, Inc. | Compositions and methods for the treatment of endometriosis |
| CN108456723A (zh) * | 2018-03-21 | 2018-08-28 | 福州福瑞医学检验实验室有限公司 | 一种子宫内膜异位症风险预测的基因检测引物和试剂盒 |
| EP3781945A4 (en) * | 2018-04-20 | 2022-04-27 | The Board of Regents of the University of Texas System | COMPOSITIONS AND METHODS FOR TREATMENT OF ENDOMETRIOSIS |
| US11906529B1 (en) * | 2018-04-27 | 2024-02-20 | Marshall University Research Corporation | Methods for treatment and diagnosis of endometriosis |
| CA3108807A1 (en) | 2018-08-08 | 2020-02-13 | Pml Screening, Llc | Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing |
| WO2024263816A2 (en) * | 2023-06-21 | 2024-12-26 | Cristcot Llc | Development and validation of the hemorrhoid disease symptom impact measure |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60321356D1 (de) * | 2002-08-30 | 2008-07-10 | Oncotherapy Science Inc | Verfahren zur diagnostik von eierstock endometriose |
-
2005
- 2005-12-09 BR BRPI0520012-1A patent/BRPI0520012A2/pt not_active Application Discontinuation
- 2005-12-09 EP EP05853605A patent/EP1848818A1/en not_active Withdrawn
- 2005-12-09 MX MX2007009562A patent/MX2007009562A/es not_active Application Discontinuation
- 2005-12-09 AU AU2005327929A patent/AU2005327929A1/en not_active Abandoned
- 2005-12-09 CA CA002596932A patent/CA2596932A1/en not_active Abandoned
- 2005-12-09 KR KR1020077021464A patent/KR20080016789A/ko not_active Withdrawn
- 2005-12-09 WO PCT/US2005/044723 patent/WO2006091254A1/en not_active Ceased
- 2005-12-09 JP JP2007556134A patent/JP2008537474A/ja not_active Withdrawn
- 2005-12-09 CN CNA2005800484494A patent/CN101124340A/zh active Pending
- 2005-12-09 US US11/884,402 patent/US20090208939A1/en not_active Abandoned
-
2007
- 2007-07-30 IL IL184920A patent/IL184920A0/en unknown
- 2007-09-11 ZA ZA200707752A patent/ZA200707752B/xx unknown
- 2007-09-18 NO NO20074762A patent/NO20074762L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1848818A1 (en) | 2007-10-31 |
| NO20074762L (no) | 2007-11-16 |
| IL184920A0 (en) | 2007-12-03 |
| US20090208939A1 (en) | 2009-08-20 |
| JP2008537474A (ja) | 2008-09-18 |
| BRPI0520012A2 (pt) | 2009-04-14 |
| WO2006091254A1 (en) | 2006-08-31 |
| CN101124340A (zh) | 2008-02-13 |
| MX2007009562A (es) | 2008-03-11 |
| KR20080016789A (ko) | 2008-02-22 |
| ZA200707752B (en) | 2010-05-26 |
| CA2596932A1 (en) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090208939A1 (en) | Identification of Molecular Diagnostic Markers for Endometriosis in Blood Lymphocytes | |
| US9803243B2 (en) | Biomarkers for diagnosis of stroke and its causes | |
| JP5179177B2 (ja) | 膀胱癌を検出するための尿マーカー | |
| US9746479B2 (en) | Methods and compositions to predict and detect acute rejection | |
| US11136626B2 (en) | Biomarkers for the diagnosis of lacunar stroke | |
| US20110166028A1 (en) | Methods for predicting treatment response based on the expression profiles of biomarker genes in notch mediated cancers | |
| CA2524173A1 (en) | Methods for diagnosing aml and mds differential gene expression | |
| WO2007100913A2 (en) | Genes differentially expressed in bipolar disorder and/or schizophrenia | |
| US8257917B2 (en) | Salivary biomarkers for Sjögren's syndrome | |
| KR101657051B1 (ko) | 만성폐쇄성폐질환 진단용 마커 조성물 | |
| US20130217656A1 (en) | Methods and compositions for diagnosing and treating lupus | |
| WO2006132983A2 (en) | Differential expression of molecules associated with vascular disease risk | |
| WO2014173986A2 (en) | Methods for diagnosing and monitoring the response to treatment of hepatocellular carcinoma | |
| KR101540052B1 (ko) | 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 kdm4d | |
| EP2454388A2 (en) | Methods and kits used in assessing cancer risk | |
| KR20170095761A (ko) | TMEM57 또는 NudC 유전자를 이용한 백혈병 진단용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |